Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEP1B | Q16820 | 1/20 | 0.63 |
| ▸ | CA1 | P00915 | 3/20 | 0.50 |
| ▸ | CA2 | P00918 | 3/20 | 0.50 |
| ▸ | MMP1 | P03956 | 3/20 | 0.50 |
| ▸ | MMP2 | P08253 | 3/20 | 0.50 |
| ▸ | MMP9 | P14780 | 3/20 | 0.50 |
| ▸ | MMP8 | P22894 | 3/20 | 0.50 |
| ▸ | MMP13 | P45452 | 3/20 | 0.50 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.49 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | IDH1 | O75874 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.41 |
| ▸ | BRD1 | O95696 | 1/20 | 0.41 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15881204 | 0.85 | CA1 (0.50) | MEP1BCA1CA2MMP1MMP2 | |
| SCHEMBL2525525 | 0.83 | LMNA (0.65) | MEP1BMCL1USP30LMNAALDH1A1 | |
| SCHEMBL5472657 | 0.81 | MEP1B (0.55) | MEP1BMCL1USP30LMNAALDH1A1 | |
| SCHEMBL6257763 | 0.81 | MEP1B (0.55) | MEP1BMCL1USP30LMNAALDH1A1 | |
| SCHEMBL15880801 | 0.81 | ALDH1A1 (0.60) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL11962947 | 0.81 | CA1 (0.53) | MEP1BCA1CA2MMP1MMP2 | |
| SCHEMBL29536726 | 0.81 | CA1 (0.53) | MEP1BCA1CA2MMP1MMP2 | |
| SCHEMBL6766551 | 0.79 | MEP1B (0.51) | MEP1BMCL1USP30LMNAALDH1A1 | |
| SCHEMBL14676763 | 0.77 | MEP1B (0.55) | MEP1BMMP1MMP2MMP9MMP13 | |
| SCHEMBL1767675 | 0.77 | CA1 (0.53) | CA1CA2MMP1MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110179777-B | Pharmaceutical compositions comprising nitroxyl donors | 卡尔迪奥克斯尔制药公司 | 2022-07-15 | — | — | CN | disclosed |
| US-11304924-B2 | Pharmaceutical compositions comprising nitroxyl donors | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2022-04-19 | — | — | US | disclosed |
| US-11083704-B2 | Method of administering nitroxyl donating compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-08-10 | — | — | US | disclosed |
| EP-3427728-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NITROXYL DONORS | CARDIOXYL PHARMACEUTICALS INC (US) | 2021-07-07 | — | — | EP | disclosed |
| EP-3427728-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NITROXYL DONORS | CARDIOXYL PHARMACEUTICALS INC (US) | 2021-07-07 | — | — | EP | disclosed |
| US-20200163929-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NITROXYL DONORS | CARDIOXYL PHARMACEUTICALS, INC. | 2020-05-28 | — | — | US | disclosed |
| US-20200163929-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NITROXYL DONORS | CARDIOXYL PHARMACEUTICALS, INC. | 2020-05-28 | — | — | US | disclosed |
| US-10548872-B2 | Pharmaceutical compositions comprising nitroxyl donors | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2020-02-04 | — | — | US | disclosed |
| US-10548872-B2 | Pharmaceutical compositions comprising nitroxyl donors | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2020-02-04 | — | — | US | disclosed |
| US-20190343790-A1 | METHOD OF ADMINISTERING NITROXYL DONATING COMPOUNDS | CARDIOXYL PHARMACEUTICALS, INC. | 2019-11-14 | — | — | US | disclosed |
| EP-2945621-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NITROXYL DONORS | CARDIOXYL PHARMACEUTICALS INC (US) | 2018-10-17 | — | — | EP | disclosed |
| WO-2018128999-A1 | METHOD OF ADMINISTERING NITROXYL DONATING COMPOUNDS | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2018-07-12 | — | — | WO | disclosed |
| US-20150366977-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NITROXYL DONORS | CARDIOXYL PHARMACEUTICALS, INC. | 2015-12-24 | — | — | US | disclosed |
| US-20150366977-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NITROXYL DONORS | CARDIOXYL PHARMACEUTICALS, INC. | 2015-12-24 | — | — | US | disclosed |
| US-20150366977-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NITROXYL DONORS | CARDIOXYL PHARMACEUTICALS, INC. | 2015-12-24 | — | — | US | disclosed |
| EP-2945621-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NITROXYL DONORS | Cardioxyl Pharmaceuticals, Inc. (US) | 2015-11-25 | — | — | EP | disclosed |
| WO-2014113700-A9 | PHARMACEUTICAL COMPOSITIONS COMPRISING NITROXYL DONORS | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2014-10-09 | — | — | WO | disclosed |
| WO-2014113700-A9 | PHARMACEUTICAL COMPOSITIONS COMPRISING NITROXYL DONORS | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2014-10-09 | — | — | WO | disclosed |
| WO-2014113700-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NITROXYL DONORS | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2014-07-24 | — | — | WO | disclosed |
| WO-2014113700-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NITROXYL DONORS | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2014-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10548872-B2 | Pharmaceutical compositions comprising nitroxyl donors | TNNT2, TNNI3, NQO1 | MEP1B 4853/4885CA1 4828/4885CA2 4041/4885 |
| US-20200163929-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NITROXYL DONORS | TNNT2, TNNI3, NQO1 | MEP1B 4853/4885CA1 4828/4885CA2 4041/4885 |
| US-20150366977-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NITROXYL DONORS | TNNT2, TNNI3, NQO1 | MEP1B 4853/4885CA1 4828/4885CA2 4041/4885 |
| US-11083704-B2 | Method of administering nitroxyl donating compounds | NQO1, UGT1A3, NNMT | MEP1B 3799/4885CA1 2607/4885CA2 3672/4885 |
| US-20190343790-A1 | METHOD OF ADMINISTERING NITROXYL DONATING COMPOUNDS | NQO1, UGT1A3, NNMT | MEP1B 3799/4885CA1 2607/4885CA2 3672/4885 |
| US-11304924-B2 | Pharmaceutical compositions comprising nitroxyl donors | TNNT2, TNNI3, NQO1 | MEP1B 4853/4885CA1 4828/4885CA2 4041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.